Gazyva (Obinutuzumab) waa dawo u eg Rituxan (rituximab) waxaana lagu baarayaa noocyada kala duwan ee kansarrada dhiigga, oo ay ku jiraan daraasado badan oo kiliinik ah oo ku yaal Non-Hodgkin's Lymphoma (NHL). Sida Rituxan, Gazyva waxaa loo isticmaalaa iyadoo loo adeegsanayo kiimiko ku daweynta kansarka dhiigga qaarkood. Daroogada Genentech iyo Roche waxay ogsoon yihiin in ay jiraan daraasado badan oo socda oo isbarbardhigaya obinutuzumab oo leh rituximab lymphoma oo aan qotom-dheecaan lahayn iyo laf-dhabarka weyn ee B-cell B-cell.
Gazyva hadda waa FDA loo ogolaaday isticmaalka bukaannada qaarkood oo qaba lymphoma follicles, marka lagu daro isticmaalka isticmaalka lymphocytic leukemia, ama CLL. CLL, Gazyva waxaa lagu daraa chlorambucil; Lymphoma, gaasta waxaa lagu daraa bendamustine.
Ku saabsan Lymphoma ee Folicicular Lymphoma
In kasta oo aanay ahayn lymphoma ugu badan, lymphoma follicles ayaa ku jira noocyada ugu caansan ee lymfoma ee lagu ogaado. Labada qaybood ee asaasiga ah ee lymphoma waa Hodgkin's iyo non-Hodgkin's lymphoma. Lymphoma lymphoma waa nooca aan ahayn Hodgkin oo ah midka ugu caansan ee maqaarka, ama gaabis sii kordhaysa, non-Hodgkin's lymphomas (NHL).
Inkasta oo uu si tartiib ah u sii korayo, haddana waa kansar aan la daweyn karin taas oo noqoneysa mid adag in la daaweeyo mar kasta oo ay soo noqoto. Lymphoma lymphoma ayaa ku fadhiya mid ka mid ah shantii xaaladood ee NHL ee Maraykanka, halkaas oo lagu qiyaasay in in ka badan 14,000 kiis oo cusub lagu ogaan doono 2015.
Maaddaama bukaanno badani si guul leh u hayn karaan kansarka, dawooyinka cusub ayaa si gaar ah loogu soo dhaweynayaa.
Gawaarida Lymphoma
"Dadka qaba lymphoma ee cudurkeenaha ku soo noqda ama ka sii daraya inkastoo daaweynta Rituxan-ku jiro oo u baahan daaweyn dheeraad ah waxay u baahan tahay fursado badan sababtoo ah cudurku wuxuu noqonayaa mid aad u adag in la daweeyo mar kasta oo ay soo noqoto," ayuu yiri Sandra Horning, MD, madaxa caafimaadka iyo madaxa Global Horumarin.
"Gazyva iyo bendamustin waxay bixisaa doorasho daaweyn oo cusub oo loo isticmaali karo ka dib dib u noqosho si loo yareeyo khatarta sii socoshada ama dhimashada."
Oggolaanshaha FDA ee Gazyva waxay ku saleysneyd natiijooyinka ka soo baxay Daraasada Phase III GADOLIN, taas oo muujisay in dadka qaba lymphoma ee cudurkeenu uu soo batay intii lagu jiray ama lix bilood ka hor daaweynta Rituxan-ku-salaysan, Gazyva iyo bendamustine oo ay ku xigto Gazyva oo keliya ayaa muujisay 52 hoos u dhac boqolkiiba halista cudurka sii xumaanaya ama dhimashada (badbaadada aan lahayn bilaashka, PFS), marka la barbardhigo bendamustine oo keliya.
Sidee Gacanigu u shaqeynayaa?
Gazyva, sida Rituxan, waa unug monoclonal ah. Taasi waa, waa nooc gaar ah oo antibio ah oo injineernimo abuuray oo ay soo saareen kuwa soo saarey. Badeecada kama dambaysta ah ayaa lagu xiraa bac ah sida dareeraha oo lagu siiyay faleebo xidid.
Sida Rituxan, Gazywa ayaa bartilmaameed u ah antibiyanka CD20. Daawada CD20 waxay u egtahay dhammaystirnaanta calaamadaynta - waa kakool barar ah oo ku yaala dusha sare ee unugyada qaarkood, oo ay ku jiraan unugyada dhiiga cad ee loo yaqaanno B-lymphocytes, ama unugyada B. Noocyo aan weli qarsooneyn B, oo loo yaqaanno unugyada pre-B , ayaa sidoo kale leh antibiyadan CD20.
Marka obinutuzumab ku xirto CD20, tani waxay keenaysaa dhimashada iyo daadinta furan ee unugyada B. Waxay sidaas sameeyaan iyagoo qoraya unugyada kale ee difaaca si ay u qabtaan shaqada, iyagoo si toos ah u-hawlgalaya calaamadaha dhimashada iyo / ama dhaqaajinta wax la yiraahdo isdaba-joogga is-qabsiga - taxane kiimiko ah oo isdaba-joog ah ayaa habka difaacu u adeegsanayaa, muujinaya baahida loo qabo in la raadiyo lana baabi'iyo.
Sidee ayuu Gazyva uga duwan yahay Rituxan? Hase yeeshe, sida laga soo xigtay kuwa daroogada ah, Gazyva waxaa loo maleynayaa in uu leeyahay awood korodh ah oo lagu soo afjaro geerida gacanta tooska ah - wax la yiraahdo cytotoxicity-ku-xirmidda unugyada jirka (ADCC) - iyo waxa ay ka dhigeysaa waxqabad weyn sidii ay u qori lahaayeen nidaamka difaaca jirka si loo weeraro B-unugyada marka la barbardhigo rituximab. Dhab ahaantii, daraasad qadarin ah, Gazyva ayaa gaarsiisay 35-laab kordhin ADCC marka loo eego Rituxan. Gazyva waxay sidoo kale hawlgelisay calaamadaha dhimashada ee gudaha unugyada B ee daraasadaha qadada ah.
Waxyaabaha kale ee saameynaya
Nabadgelyada Gawaarida waxaa lagu qiimeeyey 392 bukaan oo qaba cudurka NHL, oo boqolkiiba 81 ay qabeen lymfoma.
Bukaannada qaba lymphoma follicles, waxyeellooyinka ugu badan ee la arko waxay u dhigantaa guud ahaan tirada guud ee naafada NHL.
Dhibaatooyinka ugu badan ee Gawaarida waxaa ka mid ah ficil-celinta faleebo, dhiig-yare, dhiig-dufan, qufac, shuban, caloosha, qandho, hoos-u-dhacyo tirtirma, matagga, infekshinka neefta sare, cunto yari, hoos udhac ama muruq xanuun, sinusitis, infekshinka unugyada dhiigga ee cas, hooseeya oo daciif ah, iyo infekshinka kaadida.
Dhibaatooyinka ka yimaada calaamadaha nolosha ee khatarta ah ayaa lagu soo waramayaa warar sheegaya dhakhtarrada, mararka qaarkood waxay qaataan foomka "digniin calaamadeed." Gawaarida, digniinta calaamaddan waxaa ka mid ah macluumaadka ku saabsan laba infekshanka fayraska: Cagaarshowga B (Hepatitis B Virus) (HBV) dib u soo noqoshada xaaladaha qaarkood oo sababay dhaawac beerka ah iyo dhimasho; iyo Jir-ka-qaadista jeermiska JCB Progressive Multipocal Leukoencephalopathy (PML) taasoo keentay dhimasho.
Faahfaahin buuxda oo ku saabsan ammaanka iyo waxtarka guud ee Gazyva ee lymphoma, fadlan ka eeg Macluumaadka Daawada Gazyva.
Ilaha:
1. Macluumaadka Daawada Gazyva.
2. Mössner E, Brünker P, Moser S, et al. Kordhinta waxtarka daaweynta antibodyka CD20 iyada oo loo marayo injineernimada nooc ka mid ah nooca II anti-anti-CD20 antibody leh habka tooska iyo difaaca jirka ee waxtar u leh unugyada B-cell ee dhexdhexaad ah. Dhiiga . 2010; 115 (22): 4393-4402.
3. Herter S, Herting F, Mundigl O, et al. Waxqabadka takhasuska ee nooca II CD20 antibody GA101 (obinutuzumab) marka la barbar dhigo rituximab iyo ofatumumab oo ku jira maadada fitamiinada iyo xenograft-ka. Mol Kansar ah . 2013; 12 (10): 2031-2042.
4. Klein C, Lammens A, Schäfer W, et al. Isdhexgelinta Epitope ee antiboyaaliga ah ee lagu beegsanayo CD20 iyo xiriirka ay leeyihiin guryaha shaqeynta. mAbs . 2013; 5 (1): 22-33.